In vivo instability of 177Lu‐DOTATATE during peptide receptor radionuclide therapy.

MLA

Lubberink, Mark, et al. “In Vivo Instability of 177Lu‐DOTATATE during Peptide Receptor Radionuclide Therapy.” Journal of Nuclear Medicine, vol. 61, no. 10, Oct. 2020, pp. 1–16. EBSCOhost, https://doi.org/10.2967/jnumed.119.237818.

APA

Lubberink, M., Wilking, H., Öst, A., Ilan, E., Sandström, M., Andersson, C., Fröss-Baron, K., Velikyan, I., & Sundin, A. (2020). In vivo instability of 177Lu‐DOTATATE during peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 61(10), 1–16. https://doi.org/10.2967/jnumed.119.237818

Chicago

Lubberink, Mark, Helena Wilking, Amalia Öst, Ezgi Ilan, Mattias Sandström, Camilla Andersson, Katarzyna Fröss-Baron, Irina Velikyan, and Anders Sundin. 2020. “In Vivo Instability of 177Lu‐DOTATATE during Peptide Receptor Radionuclide Therapy.” Journal of Nuclear Medicine 61 (10): 1–16. doi:10.2967/jnumed.119.237818.